Rattanawong, Wanakorn

Loading...
Thumbnail Image
Preferred name
Rattanawong, Wanakorn
Alternative Name
Rattanawong, W.
Main Affiliation
Email
wanakorn.ra@kmitl.ac.th

Settings

Now showing 1 - 2 of 2
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Correction to: Filling the data gap on CGRP mAb therapy in low- to middle-income countries in Southeast Asia: insights from a real-world study in Thailand (The Journal of Headache and Pain, (2024), 25, 1, (150), 10.1186/s10194-024-01859-3)
    (2025-12-01)
    Anukoolwittaya, Prakit
    ;
    Hiransuthikul, Akarin
    ;
    Pongpitakmetha, Thanakit
    ;
    Thanprasertsuk, Sekh
    ;
    Rattanawong, Wanakorn
    In this article reference 13 was Asawavichienjinda T, Imruetaijaroenchoke W, Phanthumchinda K (2020) Thai-version Migraine Disability Assessment (MIDAS) questionnaire: concurrent validity, test-retest reliability, internal consistency, and factors predictive for migraine-related disability. Asian Biomed (Res Rev News) 14(4):139–150 but it should have been Vongvaivanich K, Yongprawat T, Jindawong N, Chansakul C (2018) Test-Retest Reliability of the Thai Migraine Disability Assessment (Thai-MIDAS) Questionnaire in Thai Migraine Patients. Bangk Med J 14(1):10–10. The original article has been updated. The authors would like to apologize for any inconvenience caused.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Correction: Diagnosis challenges and accessibility barriers to migraine management in Southeast Asia: results from the South-East Asia Local breAch on MigraiNe Treatment (SEALANT) study (The Journal of Headache and Pain, (2026), 27, 1, (47), 10.1186/s10194-026-02295-1)
    (2026-12-01)
    Rattanawong, Wanakorn
    ;
    Hiransuthikul, Akarin
    ;
    Anukoolwittaya, Prakit
    ;
    Pongpitakmetha, Thanakit
    ;
    Thanprasertsuk, Sekh
    In the section Survey and outcomes of this article, the components of the questionnaire were incorrectly labeled using the manuscript-style headings “Introduction,” “Methods,” “Results,” “Discussion,” and “Conclusion.” These terms were intended solely to denote internal sections of the questionnaire and do not correspond to the standard structural sections of the manuscript. To avoid confusion, these labels have been replaced with “Section 1,” “Section 2,” “Section 3,” “Section 4,” and “Section 5,” respectively. The correct and incorrect version of the text is presented below and the original article has been corrected. The survey comprised five main sections, each designed to explore different aspects of migraine care and physician perspectives. Section 1 collected demographic data. Section 2 focused on barriers to migraine diagnosis, covering issues such as diagnostic accuracy, time to diagnosis, hospital workload, and use of headache diaries and patient education. Section 3 explored acute migraine treatment, including medication availability, the proportion of patients using acute medications, issues of medication underuse (timing and efficacy), and awareness of MOH. Section 4 explored preventive treatment, including access to preventive medications, availability of calcitonin gene-related peptide (CGRP)–targeted therapies, and physicians’ views on their use. Section 5 explored migraine-related stigma and its impact on patients’ quality of life; these findings will be reported separately. The survey comprised five main sections, each designed to explore different aspects of migraine care and physician perspectives. Section “Introduction” collected demographic data. Section “Methods” focused on barriers to migraine diagnosis, covering issues such as diagnostic accuracy, time to diagnosis, hospital workload, and use of headache diaries and patient education. Section “Results” explored acute migraine treatment, including medication availability, the proportion of patients using acute medications, issues of medication underuse (timing and efficacy), and awareness of MOH. Section “Discussion” explored preventive treatment, including access to preventive medications, availability of calcitonin gene-related peptide (CGRP)–targeted therapies, and physicians’ views on their use. Section “Conclusion” explored migraine-related stigma and its impact on patients’ quality of life; these findings will be reported separately.